KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Globus Medical (GMED) Research & Development (2016 - 2025)

Historic Research & Development for Globus Medical (GMED) over the last 15 years, with Q3 2025 value amounting to $38.1 million.

  • Globus Medical's Research & Development rose 759.47% to $38.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $144.5 million, marking a year-over-year decrease of 2086.93%. This contributed to the annual value of $163.8 million for FY2024, which is 3204.9% up from last year.
  • As of Q3 2025, Globus Medical's Research & Development stood at $38.1 million, which was up 759.47% from $40.0 million recorded in Q2 2025.
  • In the past 5 years, Globus Medical's Research & Development registered a high of $57.3 million during Q1 2024, and its lowest value of $14.9 million during Q1 2021.
  • Moreover, its 5-year median value for Research & Development was $29.3 million (2023), whereas its average is $30.0 million.
  • Per our database at Business Quant, Globus Medical's Research & Development surged by 23476.81% in 2021 and then plummeted by 6176.75% in 2022.
  • Over the past 5 years, Globus Medical's Research & Development (Quarter) stood at $51.0 million in 2021, then tumbled by 61.77% to $19.5 million in 2022, then skyrocketed by 167.86% to $52.3 million in 2023, then plummeted by 36.06% to $33.4 million in 2024, then grew by 13.95% to $38.1 million in 2025.
  • Its Research & Development stands at $38.1 million for Q3 2025, versus $40.0 million for Q2 2025 and $33.1 million for Q1 2025.